PainReform

Company Overview

Snapshot

Founded in December 2007, PainReform operates with 1–10 employees and has raised $46.3 million across 5 funding rounds from 4 investors. The company went public on NASDAQ in September 2020.

Business overview

PainReform is a clinical-stage specialty pharmaceutical company that focuses on reformulating established therapeutics. The company's proprietary drug-delivery system is designed to provide extended post-surgical pain relief without repeated dose administration, aiming to reduce the reliance on opiates. PainReform incorporates generic drugs with proven safety and efficacy into its extended-release drug-delivery system to improve therapy and leverages the FDA's 505(b)(2) regulatory pathway to streamline drug approval. Its lead product, PRF-110, is a ropivacaine-based local anesthetic targeting the post-operative pain relief market. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery.

Strategic signal

In May 2026, PRF Technologies, an entity associated with PainReform, announced that its PRF-110 product demonstrated sustained 72-hour analgesic activity comparable to approved commercial benchmarks in a head-to-head preclinical study. This preclinical validation of PRF-110's extended pain relief capabilities sends a strong signal to investors about the product's potential efficacy and market competitiveness, particularly in addressing the need for non-opiate post-surgical pain management.

Company Intelligence Q&A

When did PainReform go public?

PainReform went public on NASDAQ in September 2020, raising $23 million in its Initial Public Offering.

What was a significant recent development for PRF-110?

In May 2026, PRF Technologies announced that PRF-110 demonstrated sustained 72-hour analgesic activity comparable to approved, commercially available benchmarks in a head-to-head preclinical study.

What is PainReform's strategy for drug development?

PainReform's strategy involves incorporating generic drugs with proven safety and efficacy into its proprietary extended-release drug-delivery system to create improved therapies. The company utilizes the FDA's 505(b)(2) regulatory pathway to expedite drug approval by referencing existing data.

What was the outcome of PainReform's strategic investment in LayerBio?

In August 2025, PainReform completed a strategic investment in LayerBio, aimed at entering the global cataract surgery market with a breakthrough non-opiate, non-steroidal postoperative NSAID drug delivery system.

What was a recent business update from PainReform?

In March 2026, PRF Technologies provided a year-end 2025 business update, highlighting strategic progress across its healthcare and AI-driven solar platforms.